PHARMACOKINETICS OF ORAL AND INTRAVENOUS MELPHALAN DURING ROUTINE TREATMENT OF MULTIPLE-MYELOMA

被引：79

作者：

BOSANQUET, AG ^{[1
]}

GILBY, ED ^{[1
]}

机构：

[1] ROYAL UNITED HOSP,DEPT MED ONCOL,BATH BA1 3NG,AVON,ENGLAND

来源：

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY | 1982年 / 18卷 / 04期

关键词：

D O I：

10.1016/0277-5379(82)90006-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：355 / 362

页数：8

共 29 条

[1] ALBERTS DS, 1979, CLIN PHARMACOL THER, V26, P73
[2] ALBERTS DS, 1979, CLIN PHARMACOL THER, V26, P737
[3] ALEXANIAN R, 1968, BLOOD, V31, P1
[4] BEGLEITER A, 1979, CANCER RES, V39, P353
[5] BERGEL F, 1954, J CHEM SOC, V76, P2409
[6] BOSANQUET AG, UNPUB J CHROMATOGR
[7] PHARMACOLOGY OF INTRAVENOUS MELPHALAN IN PATIENTS WITH MULTIPLE-MYELOMA
BROX, L
BIRKETT, L
BELCH, A
[J]. CANCER TREATMENT REVIEWS, 1979, 6 : 27 - 32
[8] HIGH-PRESSURE LIQUID-CHROMATOGRAPHIC ANALYSIS OF MELPHALAN IN PLASMA
CHANG, SY
ALBERTS, DS
MELNICK, LR
WALSON, PD
SALMON, SE
[J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 1978, 67 (05) : 679 - 682
[9] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE
COCKCROFT, DW
GAULT, MH
[J]. NEPHRON, 1976, 16 (01) : 31 - 41
[10] CURRY SH, 1977, DRUG DISPOSITION PHA